Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate Therapies

Faculty

Hope S. Rugo, MD, FASCO
Moderator
Professor of Medicine
Winterhof Family Professor of Breast Cancer
Director, Breast Oncology and Clinical Trials Education
Medical Director, Cancer Infusion Services
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Srigowri Kota , MSN, BA, APN, AGNP-C, AOCNP
Genitourinary Medical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ
Lee S. Schwartzberg, MD, FACP
Chief, Medical Oncology and Hematology
Renown Health-Pennington Cancer Institute
Professor of Clinical Medicine
University of Nevada, Reno
Reno, NV
Deltra James
Patient/Patient Advocate
MBC Advocate and Death Doula

Statement of Need

Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents, which may hinder clinicians’ ability to implement them into practice appropriately or cause hesitancy to use them altogether.

This 90-minute live activity is led by a panel of breast cancer experts who will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Integrate the latest data on ADCs to individualize treatment for mBC based on recent clinical evidence and updated guidelines
  • Develop strategies for the management of AEs associated with ADCs used to treat patients with mBC
  • Implement strategies to mitigate BC health disparities based on specific drivers of inequity

Financial Support

Supported through an independent educational grant from Gilead Sciences, Inc.

Target Audience

Academic and community oncologists, nurse practitioners (NPs), physician associates (PAs), oncology pharmacists, and oncology nurses

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this Live Activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center

This activity is designated for 1.50 contact hours.

Note to Nurse Practitioners:
The content of this CNE activity pertains to Pharmacology.

American Nurses Credentialing Center with ILNA

This activity is designated for 1.50 contact hours.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

OCN®
Oncology Nursing Practice (Scientific Basis/Profession)
Symptom Management & Palliative Care
Psychosocial Dimensions of Care

AOCNP®/AOCNS®
Cancer Treatment
Side Effect & Symptom Management
Professional Practice

CPHON®
Cancer Treatment
Side Effect & Symptom Management

BMTCN®
Professional Performance

CBCN®
Diagnosis & Staging
Nursing Practice (Symptom Management, EoL Care, Professional)

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Accreditation Council for Pharmacy Education

This application-based activity is approved for 1.50 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007101-0000-24-001-L01-P).

PAs (AAPA)

Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 07/31/2024. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Rugo reports the following financial relationships:

Consultant: Daiichi Sankyo, Inc.; Eisai Inc.; Mylan/Viatris Inc.; and NAPO Therapeutics

Grants: Ambrx; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer Inc.; and Stemline Therapeutics, Inc.

Research Support: (all payments to UC Regents) Ambrx; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer Inc.; and Stemline Therapeutics, Inc.

Ms. Kota reports no financial relationships to disclose.

Dr. Schwartzberg reports the following financial relationships:

Advisory Board: Coherus BioSciences; Foundation Medicine, Inc.; and Helsinn

Consultant: AstraZeneca; Daiichi Sankyo, Inc.; GSK; and Seagen Inc.

Speakers Bureau: AstraZeneca; Foundation Medicine, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.

Ms. James reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Nichole Lainhart (Planning Committee)
David Modrak, PhD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com

MM-140-053124-47

Call us at 859-260-1717  •  info@ceconcepts.com

Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate Therapies
Activity Date: 05/31/2024 at 7:30 PM EST